QUARTERLY FOCUS ISSUE: PREVENTION/OUTCOMES: OUTCOMES IN ACS
Gastrointestinal Bleeding in Patients With Acute Coronary Syndromes: Incidence, Predictors, and Clinical ImplicationsAnalysis From the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) Trial
Eugenia Nikolsky, MD, PhD*,*,
Gregg W. Stone, MD*,
Ajay J. Kirtane, MD, SM*,
George D. Dangas, MD, PhD*,
Alexandra J. Lansky, MD*,
Brent McLaurin, MD ,
A. Michael Lincoff, MD ,
Frederick Feit, MD ,
Jeffrey W. Moses, MD*,
Martin Fahy, MSc*,
Steven V. Manoukian, MD||,
Harvey D. White, MD**,
E. Magnus Ohman, MD¶,
Michel E. Bertrand, MD ,
David A. Cox, MD# and
Roxana Mehran, MD*
* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
New York University, New York, New York
AnMed Health, Anderson, South Carolina
The Cleveland Clinic, Cleveland, Ohio
|| Sarah Cannon Research Institute and Hospital Corporation of America, Inc., Nashville, Tennessee
¶ Duke University, Durham, North Carolina
# Lehigh Valley Hospital, Allentown, Pennsylvania
** Auckland City Hospital, Auckland, New Zealand
 Hopital Cardiologique, Lille, France
Manuscript received April 14, 2009;
revised manuscript received July 8, 2009,
accepted July 12, 2009.
* Reprint requests and correspondence: Dr. Eugenia Nikolsky, Director, Academic Affairs, Cardiovascular Research Foundation, 111 East 59th Street, 11th Floor, New York, New York 10022 (Email: enikolsky{at}crf.org).
Objectives: We assessed the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute coronary syndromes (ACS).
Background: GIB is a potential hemorrhagic complication in patients with ACS treated with antithrombotic and/or antiplatelet medications. The clinical outcomes associated with GIB in this setting have not been systematically studied.
Methods: In the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial, 13,819 patients with moderate- and high-risk ACS, enrolled at 450 centers in 17 countries between August 2003 and December 2005, were randomized to the open-label use of 1 of 3 antithrombin regimens (heparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin monotherapy).
Results: GIB within 30 days occurred in 178 patients (1.3%). Older age, baseline anemia, longer duration of study drug administration before angiogram, smoking, ST-segment deviation 1 mm, and diabetes were identified as independent predictors of GIB. On multivariable analysis, GIB was strongly associated with 30-day all-cause mortality (hazard ratio [HR]: 4.87 [interquartile range (IQR) 2.61 to 9.08], p < 0.0001), cardiac mortality (HR: 5.35 [IQR 2.71 to 10.59], p < 0.0001), and composite ischemia (HR: 1.94 [IQR 1.14 to 3.30], p = 0.014), as well as with 1-year all-cause mortality (HR: 3.97 [IQR 2.64 to 5.99], p < 0.0001), cardiac mortality (HR: 3.77 [IQR 2.14 to 6.63], p < 0.0001), myocardial infarction (HR: 1.74 [IQR 1.01 to 3.02], p = 0.047), and composite ischemia (HR: 1.90 [IQR 1.37 to 2.64], p = 0.0001). Patients who experienced GIB had significantly higher rates of stent thrombosis compared with patients without GIB (5.8% vs. 2.4%, p = 0.009).
Conclusions: GIB is a serious condition in the scenario of ACS and is independently associated with mortality and ischemic complications.
Key Words: gastrointestinal hemorrhage bleeding coronary disease
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | CABG = coronary artery bypass grafting | | GIB = gastrointestinal bleeding | | GPI = glycoprotein IIb/IIIa inhibitor | | IQR = interquartile range | | MI = myocardial infarction | | PCI = percutaneous coronary intervention | | TIMI = Thrombolysis In Myocardial Infarction |
|
Related Article
-
Inside This Issue
J. Am. Coll. Cardiol. 2009 54: A26.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al.
Highlights of the Year in JACC 2009
J. Am. Coll. Cardiol.,
January 26, 2010;
55(4):
380 - 407.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Van de Werf
Balancing Benefit and Bleeding Risk of Antithrombotic Agents in the Individual Patient With an Acute Coronary Syndrome
Circulation,
January 5, 2010;
121(1):
5 - 7.
[Full Text]
[PDF]
|
 |
|
|